Loading market dashboard
Immutep Limited
IMMPHealthcareNASDAQAU
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
New York, New York--(Newsfile Corp. - June 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of Immutep Ltd. (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive (the "Class Period"), of the important July 6, 2026 lead plaintiff deadline.
Faruqi and Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Immutep To Contact Him
NEW YORK, June 5, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of Immutep Ltd. (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive (the "Class Period"), of the important July 6, 2026 lead plaintiff deadline.
SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug Candidate On May 5, 2026, a class action was filed on behalf of all investors who purchased or otherwise acquired Immutep Limited American Depository Receipts (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026. Immutep is an Australian-based biotechnology company focused on developing Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases.
NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts (“ADRs”) of Immutep Ltd. (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive (the “Class Period”), of the important July 6, 2026 lead plaintiff deadline.
LOS ANGELES, June 5, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Immutep Limited ("Immutep" or "the Company") (NASDAQ: IMMP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of IMMP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
LOS ANGELES, June 5, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immutep Limited ("Immutep" or "the Company") (NASDAQ: IMMP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 24, 2025 and March 12, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before July 6, 2026.
New York, New York--(Newsfile Corp. - June 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of Immutep Ltd. (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive (the "Class Period"), of the important July 6, 2026 lead plaintiff deadline.
Key Dates and Disclosure Events Shareholders Need to Know: A Chronological Record of Alleged Misrepresentations Leading to IMMP's 83% Stock Collapse NEW YORK, June 4, 2026 /PRNewswire/ -- SueWallSt encourages investors who suffered losses in Immutep Limited (NASDAQ: IMMP) to contact the firm. Those who purchased IMMP securities between March 24, 2025 and March 12, 2026 may be entitled to recover damages.
New York, New York--(Newsfile Corp. - June 4, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Immutep Limited (NASDAQ: IMMP) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Immutep securities between March 24, 2025 and March 12, 2026, both dates inclusive (the "Class Period").
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Immutep Limited ("Immutep" or the "Company") (NASDAQ: IMMP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the American Depositary Receipts (“ADRs”) of Immutep Limited (“Immutep” or the “Company”) (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive. Should You Join The Immutep Class Action Lawsuit?
SYDNEY, AUSTRALIA, June 04, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced it will present first-in-human clinical data for its lead autoimmune candidate, IMP761, at the European Alliance of Associations for Rheumatology (EULAR) Congress, in London, UK on 4th June 2026 at 1.30 pm UK time in a poster session.
New York, New York--(Newsfile Corp. - June 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of Immutep Ltd. (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive (the "Class Period"), of the important July 6, 2026 lead plaintiff deadline.
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Immutep Limited (NASDAQ: IMMP) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Immutep securities between March 24, 2025 and March 12, 2026, both dates inclusive (the “Class Period”).
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Immutep Limited (NASDAQ: IMMP) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Immutep securities between March 24, 2025 and March 12, 2026, both dates inclusive (the "Class Period").
IMMP Investors Lost $2.28 Per Share After Immutep Allegedly Concealed Red Flags That Its TACTI-004 Trial Would Fail: What Insiders Allegedly Knew Before the 83% Collapse NEW YORK, June 3, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP announces that a securities class action has been filed against Immutep Limited (NASDAQ: IMMP). YOU MAY BE AFFECTED IF YOU: Purchased IMMP ADRs between March 24, 2025 and March 12, 2026 Lost money on your Immutep investment Submit your information to recover losses or contact Joseph E.
Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP PR Newswire
LOS ANGELES, June 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Immutep Limited ("Immutep" or "the Company") (NASDAQ: IMMP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of IMMP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
New York, New York--(Newsfile Corp. - June 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of Immutep Ltd. (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive (the "Class Period"), of the important July 6, 2026 lead plaintiff deadline.
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts (“ADRs”) of Immutep Ltd. (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive (the “Class Period”), of the important July 6, 2026 lead plaintiff deadline.
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of Immutep Ltd. (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive (the "Class Period"), of the important July 6, 2026 lead plaintiff deadline.
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Immutep Limited (“Immutep” or the “Company”) (NASDAQ: IMMP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP notifies investors that Stephan Winckels, Chief Medical Officer of Immutep Limited (NASDAQ: IMMP), is named as an individual defendant in a securities class action filed on behalf of shareholders who purchased ADRs between March 24, 2025 and March 12, 2026. Find out if you qualify to recover losses from the IMMP class action. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.Immutep ADRs lost approximately.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Immutep To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Immutep between March 24, 2025 and March 12, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 2, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Immutep Limited ("Immutep" or the "Company") (NASDAQ: IMMP) and reminds investors of the July 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Immutep Limited (“Immutep” or the “Company”) (NASDAQ: IMMP) investors of the July 6, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The Immutep Class Action Lawsuit : Do you, or did you, own shares of Immutep Limited (NASDAQ: IMMP)?
NEW YORK, June 2, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Immutep Limited (NASDAQ: IMMP). Shareholders who purchased shares of IMMP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
LOS ANGELES, June 02, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immutep Limited (“Immutep” or “the Company”) (NASDAQ: IMMP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 24, 2025 and March 12, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before July 6, 2026.
New York, New York--(Newsfile Corp. - June 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of Immutep Ltd. (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive (the "Class Period"), of the important July 6, 2026 lead plaintiff deadline.
Were Immutep's Risk Warnings Adequate? The Complaint Alleges Generic Cautionary Language Could Not Shield Defendants Who Allegedly Knew TACTI-004 Faced Specific, Undisclosed Futility Risks Were Immutep's Risk Warnings Adequate? The Complaint Alleges Generic Cautionary Language Could Not Shield Defendants Who Allegedly Knew TACTI-004 Faced Specific, Undisclosed Futility Risks
New York, New York--(Newsfile Corp. - June 1, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Immutep Limited (NASDAQ: IMMP) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Immutep securities between March 24, 2025 and March 12, 2026, both dates inclusive (the "Class Period").
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Immutep To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Immutep between March 24, 2025 and March 12, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 1, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Immutep Limited ("Immutep" or the "Company") (NASDAQ: IMMP) and reminds investors of the July 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
LOS ANGELES, June 1, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immutep Limited ("Immutep" or "the Company") (NASDAQ: IMMP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 24, 2025 and March 12, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before July 6, 2026.
NEW YORK, May 31, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Immutep Limited (NASDAQ: IMMP) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Immutep securities between March 24, 2025 and March 12, 2026, both dates inclusive (the “Class Period”).
NEW YORK, May 31, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Immutep Limited (NASDAQ: IMMP) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Immutep securities between March 24, 2025 and March 12, 2026, both dates inclusive (the "Class Period").
New York, New York--(Newsfile Corp. - May 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of Immutep Ltd. (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive (the "Class Period"), of the important July 6, 2026 lead plaintiff deadline.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Immutep To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Immutep between March 24, 2025 and March 12, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - May 31, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Immutep Limited ("Immutep" or the "Company") (NASDAQ: IMMP) and reminds investors of the July 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Immutep To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Immutep between March 24, 2025 and March 12, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - May 30, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Immutep Limited ("Immutep" or the "Company") (NASDAQ: IMMP) and reminds investors of the July 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
NEW YORK, May 30, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of Immutep Ltd. (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive (the "Class Period"), of the important July 6, 2026 lead plaintiff deadline.
NEW YORK, May 30, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts (“ADRs”) of Immutep Ltd. (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive (the “Class Period”), of the important July 6, 2026 lead plaintiff deadline.
NEW YORK, May 29, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of Immutep Ltd. (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive (the "Class Period"), of the important July 6, 2026 lead plaintiff deadline.
New York, New York--(Newsfile Corp. - May 29, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Immutep Limited (NASDAQ: IMMP) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Immutep securities between March 24, 2025 and March 12, 2026, both dates inclusive (the "Class Period").
LOS ANGELES, May 29, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immutep Limited (“Immutep” or “the Company”) (NASDAQ: IMMP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 24, 2025 and March 12, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before July 6, 2026.
NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Immutep Limited (NASDAQ: IMMP).
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Immutep To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Immutep between March 24, 2025 and March 12, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - May 29, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Immutep Limited ("Immutep" or the "Company") (NASDAQ: IMMP) and reminds investors of the July 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
New York, New York--(Newsfile Corp. - May 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of Immutep Ltd. (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive (the "Class Period"), of the important July 6, 2026 lead plaintiff deadline.
NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Immutep Limited ("Immutep" or the "Company") (NASDAQ: IMMP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Immutep Limited (“Immutep” or the “Company”) (NASDAQ: IMMP) investors of the July 6, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The Immutep Class Action Lawsuit : Do you, or did you, own shares of Immutep Limited (NASDAQ: IMMP)?
Notice to Pension Funds, Asset Managers, and Fiduciaries Holding IMMP: An 83% Single-Day Loss in Immutep ADRs Raises Urgent Questions About Portfolio Exposure and Fiduciary Recovery Obligations NEW YORK, May 28, 2026 /PRNewswire/ -- Institutional investors holding positions in Immutep Limited (NASDAQ: IMMP) during the period from March 24, 2025 through March 12, 2026 may wish to evaluate lead plaintiff opportunities in a pending securities class action. Request an institutional investor loss assessment.
SYDNEY, AUSTRALIA, May 28, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announced results from a systematic evaluation of 5 clinical trials of eftilagimod alfa ("efti") an antigen-presenting cell (APC) activator in combination with standard-of-care (SOC) therapies in late-stage cancer patients.
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of Immutep Ltd. (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive (the "Class Period"), of the important July 6, 2026 lead plaintiff deadline.
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts (“ADRs”) of Immutep Ltd. (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive (the “Class Period”), of the important July 6, 2026 lead plaintiff deadline.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Immutep To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Immutep between March 24, 2025 and March 12, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - May 27, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Immutep Limited ("Immutep" or the "Company") (NASDAQ: IMMP) and reminds investors of the July 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Immutep Limited (NASDAQ: IMMP) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Immutep securities between March 24, 2025 and March 12, 2026, both dates inclusive (the “Class Period”).
Immutep Projected TACTI-004 Would Deliver a "New Standard of Care" for Lung Cancer Patients. Instead, the Trial Was Stopped for Futility After Enrolling Just Half Its Target, and IMMP Investors Lost $2.28 Per Share.
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the American Depositary Receipts (“ADRs”) of Immutep Limited (“Immutep” or the “Company”) (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive. Should You Join The Immutep Class Action Lawsuit?
New York, New York--(Newsfile Corp. - May 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of Immutep Ltd. (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive (the "Class Period"), of the important July 6, 2026 lead plaintiff deadline.
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Immutep Limited (“Immutep” or the “Company”) (NASDAQ: IMMP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
New York, New York--(Newsfile Corp. - May 26, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Immutep Limited (NASDAQ: IMMP) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Immutep securities between March 24, 2025 and March 12, 2026, both dates inclusive (the "Class Period").
